FDA Approves Kebilidi Gene Therapy for Rare AADC Deficiency, Targeting Improved Motor Function

The FDA has approved Kebilidi (eladocagene exuparvovec-tneq), a pioneering gene therapy designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency, a rare disorder impacting neurotransmitter production, crucial for muscle and cognitive function. This treatment, the first of its kind for AADC, involves a brain-targeted infusion to increase dopamine production. In clinical studies, Kebilidi showed promising results in improving motor function in young patients.

The approval process, supported by Accelerated Approval and Priority Review, highlighted the FDA’s commitment to advancing treatments for rare conditions. The FDA also authorized the SmartFlow Neuro Cannula by ClearPoint Neuro, Inc., as the device to administer Kebilidi. Approval was granted to PTC Therapeutics, Inc.